The accumulation of somatic cancer-associated mutations in HSCs, as observed in CHIP, enhances the risk of developing a hematologic neoplasm such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). This evidence concerns the gene STUB1 and acute myeloid leukemia.